Isomorphic Labs raised $2.1 billion in a funding round led by Thrive Capital to scale its artificial intelligence-driven drug discovery platform. The round included existing backers Alphabet and Google Ventures alongside new investors MGX, Temasek, and CapitalG (a new backer). This capital injection supports a broader industry push to use AI for shortening drug development timelines and reducing research costs.
Isomorphic Labs raises 2.1 billion dollars for AI drug work
Isomorphic Labs has secured 2.1 billion dollars in a funding round led by Thrive Capital to expand its AI-driven drug design engine. The Alphabet spin-off plans to launch its first clinical trials by late 2026 as it works to accelerate medical research and development timelines.
Xurve View
Insights:
Xurve View








